2021-11-02T10:56:46-05:00 2020-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2020-01-01 352577906 MAXAID MAXA 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA M PEARCE CFO & VP, ADMINISTRATION 4257788660 2021-10-29 1 PATRICIA PEARCE 999009999 JENNIFER BECKER HARRIS P00183358 4254544919 2021-10-29 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z PATRICIA M PEARCE 1107 NE 45TH NO 230 SEATTLE WA 98105 521790603 0 X WWW.MAXAID.ORG X 2016 WA MAXAID IS A 501(C)(3) NON-PROFIT SUBSIDIARY OF THE MAX FOUNDATION, SUPPORTING ITS MISSION OF INCREASING GLOBAL ACCESS TO TREATMENT, CARE, AND SUPPORT FOR PEOPLE LIVING WITH CANCER. 9 8 0 8 0 0 185050573 521790603 0 0 0 0 0 0 185050573 521790603 251380063 435701949 0 0 0 0 0 0 0 5544228 3670196 256924291 439372145 -71873718 82418458 110472066 193262872 1931727 2304075 108540339 190958797 THE PRIMARY PURPOSE OF MAXAID IS TO CARRY OUT TREATMENT ACCESS SOLUTIONS FOR ONCOLOGY PRODUCTS IN LOW-AND-MIDDLE INCOME COUNTRIES IN SUPPORT OF THE MAX FOUNDATION'S MISSION. 0 0 439366618 435701949 0 MAXAID HOSTS THE MAX FOUNDATION'S COLLABORATION WITH FIVE LEADING GLOBAL HEALTHCARE MANUFACTURERS FOR HUMANITARIAN ACCESS TO EIGHT CRITICAL MEDICINES UNDER THE UMBRELLA OF MAX ACCESS SOLUTIONS. WITHIN THIS PROGRAM, ONCOLOGY PRODUCTS ARE RECEIVED FROM DRUG MANUFACTURERS AND CHANNELED TO INDIVIDUAL PATIENTS THROUGH THE MAX FOUNDATION'S NETWORK OF HEALTHCARE PROVIDERS AND TREATMENT CENTERS. IN 2020, THE COLLABORATION ENABLED THOUSANDS OF PATIENTS IN LOW- AND MIDDLE-INCOME COUNTRIES TO ACCESS MUCH NEEDED ONCOLOGY PRODUCTS THAT THEY WOULD NOT HAVE OTHERWISE BEEN ABLE TO ACCESS. ACCESS TO MEDICINES WAS ENABLED THROUGH THE MAX FOUNDATION'S PATIENT-CENTERED TREATMENT ACCESS SOFTWARE CALLED "PATS". 439366618 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 X X PATRICIA M PEARCE 4257788660 1107 NE 45TH NO 230 SEATTLE WA 98105 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 5.00 50.00 X X 0 234270 14560 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 2.00 40.00 X 0 186964 12490 PAULA BOULTBEE BOARD PRESIDENT 2.00 5.00 X X 0 0 0 TRACEY HIGGINS BOARD VICE PRESIDENT 2.00 5.00 X X 0 0 0 CURT MALLOY BOARD SECRETARY 2.00 5.00 X X 0 0 0 JERRY SCOTT CPA BOARD TREASURER 2.00 5.00 X X 0 0 0 MIKA MATSUZAKI BOARD MEMBER 2.00 5.00 X 0 0 0 JERALD JERRY RADICH MD BOARD MEMBER 2.00 5.00 X 0 0 0 SUSAN JERIAN BOARD MEMBER 2.00 5.00 X 0 0 0 GRANT RUBENSTEIN BOARD MEMBER 2.00 5.00 X 0 0 0 0 421234 27050 0 0 1 0 TANNER PHARMA CH GMBH ALTE STEINHAUSERSTRASSE 21 CHAM SZ 6330 SUPPLY CHAIN MANAGEMENT 4254499 THE MAX FOUNDATION 1107 NE 45TH NO 230 SEATTLE WA 98105 PROFESSIONAL SERVICES 3664669 2 521790603 512376126 521790603 521790603 0 0 0 435701949 435701949 4629 4629 3664669 3664669 898 898 439372145 439366618 5527 0 1406334 965215 221915 1515000 108528259 189803499 315558 979158 110472066 193262872 175969 644559 240030 263582 1515728 1395934 1931727 2304075 X 12080 1155298 108528259 189803499 108540339 190958797 110472066 193262872 82418458 0 X 0 1 X 1 0 X X X 1 THE MAX FOUNDATION 911893957 7 1 3664669 435701949 1 3664669 435701949 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 DUE TO MAX FOUNDATION 1395934 1395934 1 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS IN REGION 182147256 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 114116287 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS IN REGION 68832331 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 22733770 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS IN REGION 17695762 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN REGION 17625474 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS IN REGION 10959836 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS IN REGION 1296686 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS IN REGION 294547 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING 0 0 0 0 0 0 435407402 294547 435701949 DRUG SOUTH ASIA 16345 182147256 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SUB-SAHARAN AFRICA 9115 114116287 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG RUSSIA AND NEIGHBORING STATES 3899 68832331 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG SOUTH AMERICA 1243 22733770 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG CENTRAL AMERICA AND THE CARIBBEAN 1468 17695762 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EAST ASIA & THE PACIFIC 742 17625474 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG NORTH AMERICA 635 10959836 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG MIDDLE EAST AND NORTH AFRICA 87 1296686 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE DRUG EUROPE (INCLUDING ICELAND & GREENLAND) 8 294547 CANCER TREATMENT DRUG HIGHEST COMMERCIAL VOLUME AVERAGE WHOLESALE VALUE 0 0 0 0 0 0 PART I, LINE 2: ALL GRANTS TO FOREIGN ENTITIES OR INDIVIDUALS ARE MADE SUBJECT TO A WRITTEN AGREEMENT OR AWARD LETTER THAT CLEARLY DEFINES DELIVERABLES. THE MAX FOUNDATION MAINTAINS A PROGRAM DATABASE IN ORDER TO TRACK DOCUMENTATION OF GRANT REQUESTS, QUALIFIED GRANTEES, AND FULFILLMENT OF GRANT REQUESTS. PROGRAM STAFF MEMBERS MONITOR THE EXECUTION OF GRANT DELIVERABLES TO ENSURE THAT THE TERMS OF THE AGREEMENT ARE FULFILLED ON A TIMELY BASIS. PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON THE ACCRUAL BASIS OF ACCOUNTING. PART III ACCOUNTING METHOD: 0 0 0 0 0 0 0 0 0 PATRICIA GARCIA-GONZALEZ CHIEF EXECUTIVE OFFICER 0 224270 0 10000 0 0 0 0 0 14560 0 248830 0 0 PATRICIA M PEARCE CHIEF FINANCIAL OFFICER 0 186964 0 0 0 0 0 0 0 12490 0 199454 0 0 PART I, LINE 3 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. A WRITTEN CONTRACT AND BOARD APPROVAL ARE USED. X 29725116 512376126 HIGHEST COMM. VOL. 0 0 1 0 PART I, COLUMN (B): THE NUMBER IN COLUMN B REPRESENTS THE NUMBER OF TABS CONTRIBUED. FORM 990, PART I, LINE 6, VOLUNTEERS: THERE ARE EIGHT VOLUNTEER BOARD MEMBERS. PARTNER HEALTHCARE PROVIDERS VOLUNTEER THEIR TIME TO FULFILL ALL OBLIGATIONS RELATED TO PRESCRIBING, APPLYING FOR TREATMENT ACCESS REQUESTS ON BEHALF OF INDIVIDUAL PATIENTS, SUPPORT LOGISTICS AND OBTAINING IMPORT PERMITS FROM LOCAL HEALTHCARE AUTHORITIES, OVERSEE USE AND DISPENSATION OF DONATED PRODUCTS AND OTHER ACTIVITIES RELATED TO THEIR OBLIGATIONS WITHIN THE MAX ACCESS SOLUTIONS. IN 2020, THERE WERE 500 HEALTHCARE PROVIDERS IN OUR NETWORK. FORM 990, PART VI, SECTION A, LINE 8B COMMITTEE OVERSIGHT IS PROVIDED BY THE MAX FOUNDATION UNDER A SERVICES AGREEMENT BETWEEN THE TWO ORGANIZATIONS. FORM 990, PART VI, SECTION B, LINE 11B THE TAX RETURN IS PREPARED BY AN OUTSIDE ACCOUNTANT. AFTER PREPARATION, THE FINANCE COMMITTEE PERFORMS A REVIEW OF THE RETURN. THE RETURN IS THEN FILED WITH THE IRS. A COPY IS PROVIDED TO THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 15 NO REVIEW OF COMPENSATION WAS REQUIRED SINCE NO OFFICERS WERE PAID BY THIS ORGANIZATION. A RELATED AND SUPPORTED ORGANIZATION, THE MAX FOUNDATION, PERFORMS THE ANNUAL REVIEW PROCESS FOR THESE INDIVIDUALS AS APPLICABLE. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART VI, LINES 12, 13 AND 14: MAXAID FOLLOWS THE CONFLICT OF INTEREST, DOCUMENT RETENTION AND WHISTLEBLOWER POLICIES OF ITS SUPPORTED ORGANIZATION, THE MAX FOUNDATION. THE MAX FOUNDATION 1107 NE 45TH NO 230 SEATTLE WA 98105 911893957 EXPAND HUMANITARIAN ACCESS TO TREATMENTS FOR CANCER WA 501(C)(3) LINE 10 0 THE MAX FOUNDATION SOUTH AFRICA TRUST 10 COSMOSPLACE DOORNPOORT PRETORIA SF TO SUPPORT THE MAX FOUNDATION SF MAX FOUNDATION T 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0